Janus-activated kinases and signal transducer and activator of transcription control tumor growth response to camptothecin in human colon cancer cells

Cancer Biology and Therapy

Volumn 10, Issue 4, 2010, Pages 354-361

  Yun, Hyun Jin ^a   Kim, Sun Young ^a   Kwon, Young Yon ^a   Kim, Chun Ho ^a   Kang, Chang Mo ^a   Kim, Eun Ju ^a  

^a Korea Institute of Radiation and Medical Science   (South Korea)

Author keywords

Apoptosis; Camptothecin; Colon cancer; CPT; JAK; Janus activated kinases; Signal transducer and activator of transcription; STAT

Indexed keywords

CAMPTOTHECIN; DNA TOPOISOMERASE; JANUS KINASE 2; STAT3 PROTEIN;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; COLON CANCER; DRUG ACTIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CAMPTOTHECIN; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; COLONIC NEOPLASMS; DNA REPAIR; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE, NEOPLASM; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; HUMANS; JANUS KINASE 2; PHOSPHORYLATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 77957137452     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.4.12382     Document Type: Article

References (39)

1. Bedi A, Pasricha PJ, Akhtar AJ, Barber JP, Bedi GC, Giardiello FM, et al. Inhibition of apoptosis during development of colorectal cancer. Cancer Res 1995; 55:1811-6.
2. Ravi R, Jain AJ, Schulick RD, Pham V, Prouser TS, Allen H, et al. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL. Cancer Res 2004; 64:9105-14.
3. Darnell JE Jr. STATs and gene regulation. Science 1997; 277:1630-5.
4. Calo V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N, Russo A. STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol 2003; 197:157-68. (Pubitemid 37485244)
5. Horvath CM. STAT proteins and transcriptional responses to extracellular signals. Trends Biochem Sci 2000; 25:496-502.
6. Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000; 19:6613-26.
7. Aggarwal BB, Sethi G, Ahn KS, Sandur SK, Pandey MK, Kunnumakkara AB, et al. Targeting signal-transducer- and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci 2006; 1091:151-69.
8. Shin DS, Kim HN, Shin KD, Yoon YJ, Kim SJ, Han DC, Kwon BM. Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res 2009; 69:193-202.
9. Thoennissen NH, Iwanski GB, Doan NB, Okamoto R, Lin P, Abbassi S, et al. Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Res 2009; 69:5876-84.
10. Nielsen M, Kaltoft K, Nordahl M, Ropke C, Geisler C, Mustelin T, et al. Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc Natl Acad Sci USA 1997; 94:6764-9.
11. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 1993; 11:909-13.
12. Pommier Y, Redon C, Rao VA, Seiler JA, Sordet O, Takemura H, et al. Repair of and checkpoint response to topoisomerase I-mediated DNA damage. Mutat Res 2003; 532:173-203.
13. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006; 6:789-802.
14. Aller P, Rius C, Mata F, Zorrilla A, Cabanas C, Bellon T, Bernabeu C. Camptothecin induces differentiation and stimulates the expression of differentiation-related genes in U-937 human promonocytic leukemia cells. Cancer Res 1992; 52:1245-51.
15. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993; 85:271-91.
16. 2-phase of the cell cycle by 9-nitrocamptothecin. Lab Invest 1995; 73:118-27.
17. Traganos F, Seiter K, Feldman E, Halicka HD, Darzynkiewicz Z. Induction of apoptosis by camptothecin and topotecan. Ann N Y Acad Sci 1996; 803:101-10.
18. Lee S, Lee HS, Baek M, Lee DY, Bang YJ, Cho HN, et al. MAPK signaling is involved in camptothecin-induced cell death. Mol Cells 2002; 14:348-54.
19. Litvak DA, Papaconstantinou HT, Evers BM, Townsend CM Jr. Targeting molecular pathways with camptothecin as novel therapy for gastric cancer. J Gastrointest Surg 1999; 3:618-24.
20. Wuerzberger SM, Pink JJ, Planchon SM, Byers KL, Bornmann WG, Boothman DA. Induction of apoptosis in MCF-7:WS8 breast cancer cells by betalapachone. Cancer Res 1998; 58:1876-85.
21. Zhou Y, Gwadry FG, Reinhold WC, Miller LD, Smith LH, Scherf U, et al. Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects. Cancer Res 2002; 62:1688-95.
22. Pommier Y, Pourquier P, Urasaki Y, Wu J, Laco GS. Topoisomerase I inhibitors: selectivity and cellular resistance. Drug Resist Updat 1999; 2:307-18. (Pubitemid 30070455)
23. Berishaj M, Gao SP, Ahmed S, Leslie K, Al-Ahmadie H, Gerald WL, et al. Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res 2007; 9:32.
24. Simbulan-Rosenthal CM, Haddad BR, Rosenthal DS, Weaver Z, Coleman A, Luo R, et al. Chromosomal aberrations in PARP(-/-) mice: genome stabilization in immortalized cells by reintroduction of poly(ADP-ribose) polymerase cDNA. Proc Natl Acad Sci USA 1999; 96:13191-6.
25. Gupta S, Yan H, Wong LH, Ralph S, Krolewski J, Schindler C. The SH2 domains of Stat1 and Stat2 mediate multiple interactions in the transduction of IFNalpha signals. EMBO J 1996; 15:1075-84.
26. Pellegrini S, Dusanter-Fourt I. The structure, regulation and function of the Janus kinases (JAKs) and the signal transducers and activators of transcription (STATs). Eur J Biochem 1997; 248:615-33. (Pubitemid 27400015)
27. Pizzolato JF, Saltz LB. The camptothecins. Lancet 2003; 361:2235-42.
28. 2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res 1996; 56:4430-7.
29. Potmesil M. Camptothecins: from bench research to hospital wards. Cancer Res 1994; 54:1431-9.
30. Woessner RD, Eng WK, Hofmann GA, Rieman DJ, McCabe FL, Hertzberg RP, et al. Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content. Oncol Res 1992; 4:481-8.
31. Jansen WJ, Zwart B, Hulscher ST, Giaccone G, Pinedo HM, Boven E. CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants. Int J Cancer 1997; 70:335-40.
32. Goldwasser F, Bae I, Valenti M, Torres K, Pommier Y. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res 1995; 55:2116-21.
33. Perego P, Capranico G, Supino R, Zunino F. Topoisomerase I gene expression and cell sensitivity to camptothecin in human cell lines of different tumor types. Anticancer Drugs 1994; 5:645-9. (Pubitemid 24381882)
34. Uddin S, Hussain AR, Manogaran PS, Al-Hussein K, Platanias LC, Gutierrez MI, Bhatia KG. Curcumin suppresses growth and induces apoptosis in primary effusion lymphoma. Oncogene 2005; 24:7022-30.
35. Barton BE, Murphy TF, Shu P, Huang HF, Meyenhofer M, Barton A. Novel single-stranded oligonucleotides that inhibit signal transducer and activator of transcription 3 induce apoptosis in vitro and in vivo in prostate cancer cell lines. Mol Cancer Ther 2004; 3:1183-91.
36. Jing N, Tweardy DJ. Targeting Stat3 in cancer therapy. Anticancer Drugs 2005; 16:601-7.
37. Bhattacharya S, Ray RM, Johnson LR. STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells. Biochem J 2005; 392:335-44.
38. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74:597-608.
39. Reiterer G, Yen A. Inhibition of the janus kinase family increases extracellular signal-regulated kinase 1/2 phosphorylation and causes endoreduplication. Cancer Res 2006; 66:9083-9. (Pubitemid 44521127)